Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is The Pfizer-Biocon Insulin Deal In Trouble? Some Say It May Be Off

This article was originally published in PharmAsia News

Executive Summary

A source indicates the deal may soon see its end, which would be a setback for both companies in expanding their diabetes businesses.

Advertisement

Related Content

Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
Pfizer, Biocon Brush Off Deal Talks As Speculative, But Is There Fire Behind The Smoke?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC080507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel